Comparison of the efficacy and cost-effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients.
Weill
D
D
Zamora
M R
MR
D000407:Alabama; D000956:Antigens, Viral / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003422:Critical Care / Q000191:economics; D003586:Cytomegalovirus Infections / Q000191:economics / Q000517:prevention & control*; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D016040:Lung Transplantation; D011183:Postoperative Complications / Q000517:prevention & control; D012307:Risk Factors
D000956:Antigens, Viral; D000998:Antiviral Agents; D015774:Ganciclovir